Skin, Hair & Aesthetic
Peptides for Stretch Marks: What the Evidence Actually Shows
A clinical look at copper peptides (GHK-Cu) and Matrixyl for striae distensae. No dedicated human trial exists for either — both grade D for stretch marks specifically, despite stronger data on other skin.
Copper peptidesGHK-CuMatrixylStriae distensaeGrade D for striae
The quick verdict
No peptide has a controlled human trial for stretch marks — copper peptides and Matrixyl both grade D for striae, and here is the honest evidence comparison.
- Best overall
- Copper Peptides (GHK-Cu / Copper Tripeptide-1) — Edges ahead for striae only because its closest human collagen data was generated on thigh skin — an anatomically striae-prone site — plus broad MMP/TIMP remodeling mechanism. Still Grade D for stretch marks specifically: no controlled striae trial exists.
- Best value
- Matrixyl (Palmitoyl Pentapeptide-4) — The pivotal facial RCT used just 3 ppm (0.0003%), so an effective cosmetic dose is minuscule and inexpensive to formulate — and it has an excellent safety profile. But that data is facial photoaging, not stretch marks; Grade D for striae.
- Best for Early red/purple striae rubrae (still biologically active)
- Copper Peptides (GHK-Cu) — If any peptide plausibly helps striae, it is as a collagen-supporting adjunct on early active rubrae rather than mature white albae — but tretinoin and procedural therapy remain far better evidenced than either peptide.
How we evaluated
We ranked candidate peptides by how directly the human evidence touches stretch marks (striae distensae) — not by marketing claims. We separated striae-specific data from adjacent cosmetic data, treated GHK-Cu and copper tripeptide-1 as one molecule, and refused to inflate preclinical or off-label evidence into a striae grade. Where the strongest striae evidence points away from peptides (to tretinoin, prevention agents, and procedural therapy), we said so.
- Striae-specific human evidence. Whether any controlled human trial tested the peptide on actual stretch marks. For both candidates, this is zero — the decisive factor pinning both to Grade D.
- Anatomical relevance of adjacent data. How close the strongest available human study site is to striae-prone skin (thigh > facial), used only to break ties between two otherwise unproven candidates.
- Mechanistic fit. Whether the peptide's documented action (collagen synthesis, MMP/TIMP modulation, matrikine signaling) matches the collagen/elastin remodeling failure that defines striae.
- Topical safety and regulatory status. Local tolerability, sensitization risk, and cosmetic-ingredient status per CIR and clinical literature — noting that 'safe' is not 'effective'.
Rating scale: Ratings reflect strength of evidence FOR STRETCH MARKS, not general cosmetic evidence. Both candidates cap low because no controlled human striae trial exists for either; the half-point spread reflects only anatomical relevance of adjacent data and mechanistic fit.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Copper Peptides — GHK-Cu / Copper Tripeptide-1 | D | 2.0 | Early red/purple striae rubrae, as an unproven collagen-supporting adjunct only | Sold as a cosmetic serum/cream; varies by brand |
| 2 | Matrixyl — Palmitoyl Pentapeptide-4 (Pal-KTTKS) | D | 1.5 | Those wanting the best-tolerated cosmetic peptide, accepting it is unproven for striae | Sold as a cosmetic serum; varies by brand |
Copper Peptides — GHK-Cu / Copper Tripeptide-1
Broadest remodeling mechanism and the most anatomically relevant human data — but zero striae trials.
GHK-Cu is a naturally occurring plasma tripeptide-copper complex; "copper tripeptide-1" is simply its INCI cosmetic-labeling name, so the two are the same molecule. For stretch marks the honest grade is D: no controlled human striae trial exists, and neither the 2017 topical-management review nor the 2020 network meta-analysis of striae treatments even lists copper peptides. What it does have is the most anatomically relevant adjacent human data — a one-month controlled trial in 20 volunteers applying creams to the thighs, where the copper-binding peptide cream raised procollagen synthesis in 7 of 10 users, outperforming tretinoin, vitamin C and melatonin. That is an ultrastructural biomarker outcome on normal skin, not a stretch-mark result, and the sample is tiny. Mechanistically the fit for striae is strong on paper: GHK-Cu stimulates collagen synthesis, glycosaminoglycan and decorin production, and modulates the MMP/TIMP balance that governs matrix turnover, alongside antioxidant and anti-inflammatory effects. A frequently cited "Ash et al. 2011" 12-week copper-peptide striae RCT circulates on seller sites but cannot be located in PubMed or the named journal and should be treated as unverified. In cosmetic practice, GHK-Cu is typically formulated around 1 to 2% once or twice daily over 8 to 12 weeks — reported strictly as seen in the literature, never validated for striae.
Strengths
- Most anatomically relevant human data (procollagen rise on thigh skin, a striae-prone site)
- Broad, well-characterized remodeling mechanism: collagen synthesis plus MMP/TIMP modulation
- Generally well tolerated topically; copper's redox activity is quenched by the peptide
Weaknesses
- Zero controlled human trials for stretch marks (Grade D for striae)
- Best human data is a tiny n=20 biomarker study on normal, non-striae skin
- Patch-test needed for copper/metal sensitivity; avoid added copper in Wilson's disease
- Best for
- Early red/purple striae rubrae, as an unproven collagen-supporting adjunct only
- Pricing
- Sold as a cosmetic serum/cream; varies by brand
Source: Pickart & Margolina, Int J Mol Sci 2018 (PMC6073405)
Matrixyl — Palmitoyl Pentapeptide-4 (Pal-KTTKS)
The strongest cosmetic peptide RCT of the two — but it is facial photoaging, not stretch marks.
Matrixyl is palmitoyl-KTTKS, a five-amino-acid fragment of the pro-collagen I C-terminal propeptide with a palmitic-acid tail added to help it cross the stratum corneum. As a matrikine it signals fibroblasts that collagen has been damaged, prompting synthesis of collagen I, collagen III and IV, fibronectin and glycosaminoglycans while modestly restraining degrading enzymes. For stretch marks the grade is D: it does not appear in either authoritative striae review, and there is no controlled human striae trial. Its headline evidence is genuinely strong but off-target — a 12-week, double-blind, placebo-controlled, split-face trial in 93 women aged 35 to 55 found 3 ppm Pal-KTTKS significantly reduced facial wrinkles and fine lines versus the vehicle. That is facial photoaging, not striae, and the sequence homology to collagen and elastin that makes it a theoretical fit for stretch marks was noted only in safety analysis, never in efficacy work. It ranks just behind copper peptides here purely because its strongest human data is facial rather than on a striae-prone site. On safety it is excellent: the Cosmetic Ingredient Review judged palmitoyl pentapeptide-4 safe in cosmetics and predicted it non-sensitizing, with minimal systemic absorption because skin peptidases degrade it. In the pivotal trial the effective dose was just 3 ppm; consumer products often use higher percentages of the trade blend, with no striae-specific concentration validated.
Strengths
- Strongest cosmetic peptide RCT of the two (n=93 double-blind placebo-controlled facial trial)
- Excellent topical safety: judged safe and non-sensitizing by the CIR, minimal systemic absorption
- Well-characterized pro-collagen matrikine mechanism relevant to collagen remodeling
Weaknesses
- Zero controlled human trials for stretch marks (Grade D for striae)
- Best human data is facial photoaging — anatomically less relevant to striae than thigh-skin data
- No striae-specific concentration or duration has ever been validated
- Best for
- Those wanting the best-tolerated cosmetic peptide, accepting it is unproven for striae
- Pricing
- Sold as a cosmetic serum; varies by brand
Source: Robinson et al., Int J Cosmet Sci 2005 (PMID 18492182)
Feature comparison
| Feature | Copper Peptides — GHK-Cu / Copper Tripeptide-1 | Matrixyl — Palmitoyl Pentapeptide-4 (Pal-KTTKS) |
|---|---|---|
| Controlled human striae trial | — | — |
| Best adjacent human study | — | — |
| Study site relevance to striae | — | — |
| Evidence grade for stretch marks | — | — |
| Feature | Copper Peptides — GHK-Cu / Copper Tripeptide-1 | Matrixyl — Palmitoyl Pentapeptide-4 (Pal-KTTKS) |
|---|---|---|
| Primary mechanism | — | — |
| Topical safety profile | — | — |
| Regulatory status | — | — |
Frequently asked
Do copper peptides (GHK-Cu) actually get rid of stretch marks?
There is no controlled human trial showing copper peptides improve striae, and the two major striae reviews do not even list them among treatments. What copper peptides do have is small human evidence that they raise dermal collagen on normal skin — most relevantly a one-month study on thigh skin in which the copper-binding peptide cream boosted procollagen in seven of ten volunteers. That makes a benefit for stretch marks plausible in mechanism, but it remains unproven. For striae specifically the grade is D. A widely circulated "12-week copper-peptide striae RCT" attributed to Ash et al. 2011 could not be located in PubMed or the cited journal and should be treated as unverified.
Is Matrixyl better than copper peptides for stretch marks?
Neither is proven for stretch marks, so "better" is the wrong frame. Matrixyl has the stronger cosmetic RCT overall — a 12-week, double-blind, placebo-controlled split-face trial in 93 women showed reduced facial wrinkles — but that is facial photoaging, not striae. Copper peptides have the closer-to-relevant human data because the key study was done on thigh skin, an anatomically striae-prone site. For stretch marks specifically both peptides grade D, because neither has been tested against striae in a controlled human trial. Any ranking between them for this use is based on adjacent evidence and mechanism, not on stretch-mark outcomes.
Are GHK-Cu and copper tripeptide-1 different products?
No — they are the same molecule. GHK-Cu is glycyl-L-histidyl-L-lysine complexed with copper(II); "copper tripeptide-1" is simply the INCI cosmetic-labeling name for the same compound. If a product lists copper tripeptide-1 on its ingredient panel, that is the GHK-Cu peptide. Because they are identical, there is no meaningful GHK-Cu versus copper tripeptide-1 choice to make — the difference is only in how the ingredient is named on the label. This matters when comparing products, since two serums that look like different peptides may in fact contain the exact same active ingredient.
If not peptides, what does the evidence actually support for stretch marks?
For early red or purple striae rubrae, topical tretinoin has some supporting data, though it is limited and weak as monotherapy. For prevention, hyaluronic acid and Centella asiatica have the better evidence. For treating established stretch marks, the highest-ranked options in the 2020 network meta-analysis of 14 randomized trials were procedural: bipolar radiofrequency, fractional CO2 laser, and microneedling. None of these are peptides. In other words, peptides are not among the better-evidenced choices for striae — they sit in the plausible-but-unproven tier, well behind the energy-based and procedural interventions that the comparative literature actually endorses.
Are topical peptides safe to try on stretch marks?
Topically, both have good safety records. The Cosmetic Ingredient Review Expert Panel judged palmitoyl pentapeptide-4 safe in cosmetics and predicted it non-sensitizing, with minimal systemic absorption because skin peptidases degrade it. GHK-Cu is generally well tolerated because the copper is complexed to the peptide, which quenches copper's redox activity; transient redness or tingling can occur. Patch-test copper products first if you have copper or metal sensitivity, and people with Wilson's disease should avoid added copper. Crucially, safe is not effective — good tolerability does not mean these peptides will fade stretch marks, since there is no efficacy proof for striae.
Do stretch marks respond the same way whether they are red or white?
No. Active treatments generally perform better on early, vascular striae rubrae — the red or purple marks that are still biologically active — than on mature, atrophic striae albae, the older white or silvery marks. This pattern holds for tretinoin and for energy-based devices. There is no peptide-specific data either way for stretch marks, so any claim that a peptide can erase old white striae is unsupported. If peptides help striae at all, the most biologically plausible window is early red striae, where fibroblasts are still active, rather than long-established white marks where the remodeling response is diminished.